Evidence map›Paper›PMID 35777088›Full record

ArticleComputers in biology and medicine2022

Investigating the structure-activity relationship of marine polycyclic batzelladine alkaloids as promising inhibitors for SARS-CoV-2 main protease (M

Alaa M Elgohary, Abdo A Elfiky, Florbela Pereira, Tarek Mohamed Abd El-Aziz, Mansour Sobeh, Reem K Arafa, Amr El-Demerdash

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Computers in biology and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alaa M ElgoharyDepartment of Biophysics, Faculty of Sciences, Cairo University, Giza, 12613, Egypt.
Abdo A ElfikyDepartment of Biophysics, Faculty of Sciences, Cairo University, Giza, 12613, Egypt. Electronic address: dr_abdo@cu.edu.eg.
Florbela PereiraLAQV-REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, Universidade Nova de Lisboa, 2829-516, Caparica, Portugal.
Tarek Mohamed Abd El-AzizDepartment of Zoology, Faculty of Sciences, Minia University, El-Minia, 61519, Egypt; Department of Cellular and Integrative Physiology, University of Texas Health Science Centre at San Antonio, San Antonio, TX, 78229, USA.
Mansour SobehAgroBioSciences Department, Mohammed VI Polytechnic University (UM6P), Ben Guerir, Morocco.
Reem K ArafaDrug Design and Discovery Laboratory, Helmy Institute for Medical Sciences, Zewail City of Science and Technology, Giza, 12578, Egypt; Biomedical Sciences Program, University of Science and Technology, Zewail City of Science and Technology, Giza, 12578, Egypt.
Amr El-DemerdashDepartment of Biochemistry and Metabolism, The John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, UK; Division of Organic Chemistry, Department of Chemistry, Faculty of Sciences, Mansoura University, Mansoura, 35516, Egypt. Electronic address: Amr.El-Demerdash@jic.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over a span of two years ago, since the emergence of the first case of the novel coronavirus (SARS-CoV-2) in China, the pandemic has crossed borders causing serious health emergencies, immense economic crisis and impacting the daily life worldwide. Despite the discovery of numerous forms of precautionary vaccines along with other recently approved orally available drugs, yet effective antiviral therapeutics are necessarily needed to hunt this virus and its variants. Historically, naturally occurring chemicals have always been considered the primary source of beneficial medications. Considering the SARS-CoV-2 main protease (M

Indexed as

AlkaloidsCOVID-19 Drug TreatmentAntiviral AgentsCoronavirus 3C ProteasesHumansLigandsMolecular Docking SimulationMolecular Dynamics SimulationProtease InhibitorsSARS-CoV-2Structure-Activity RelationshipViral Nonstructural Proteins3C-like proteinase, SARS-CoV-2AlkaloidsAntiviral AgentsCoronavirus 3C ProteasesLigandsProtease InhibitorsViral Nonstructural ProteinsBatzelladinesGuanidine alkaloidsMarine spongesMolecular dockingMolecular dynamicsSARsSARS-CoV-2

Identifiers

PMID35777088
PMCPMC9212445

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.